DK3186395T3 - Transplantation af stamceller med en kombination af et middel der målretter stamceller og modulation af immunoregulatorisk signalering - Google Patents

Transplantation af stamceller med en kombination af et middel der målretter stamceller og modulation af immunoregulatorisk signalering Download PDF

Info

Publication number
DK3186395T3
DK3186395T3 DK15835482T DK15835482T DK3186395T3 DK 3186395 T3 DK3186395 T3 DK 3186395T3 DK 15835482 T DK15835482 T DK 15835482T DK 15835482 T DK15835482 T DK 15835482T DK 3186395 T3 DK3186395 T3 DK 3186395T3
Authority
DK
Denmark
Prior art keywords
stem cells
immunor
transplantation
modulation
agent
Prior art date
Application number
DK15835482T
Other languages
English (en)
Other versions
DK3186395T4 (da
Inventor
Judith A Shizuru
Kipp Andrew Weiskopf
Aaron Michael Ring
Akanksha Chhabra
Irving L Weissman
Peter Schnorr
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55400510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3186395(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK3186395T3 publication Critical patent/DK3186395T3/da
Publication of DK3186395T4 publication Critical patent/DK3186395T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
DK15835482.9T 2014-08-26 2015-08-26 Transplantation af stamceller med en kombination af et middel der målretter stamceller og modulation af immunoregulatorisk signalering DK3186395T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462041989P 2014-08-26 2014-08-26
PCT/US2015/046976 WO2016033201A1 (en) 2014-08-26 2015-08-26 Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling

Publications (2)

Publication Number Publication Date
DK3186395T3 true DK3186395T3 (da) 2019-11-25
DK3186395T4 DK3186395T4 (da) 2023-05-08

Family

ID=55400510

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15835482.9T DK3186395T4 (da) 2014-08-26 2015-08-26 Transplantation af stamceller med en kombination af et middel der målretter stamceller og modulation af immunoregulatorisk signalering
DK19198976.3T DK3656869T4 (da) 2014-08-26 2015-08-26 Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19198976.3T DK3656869T4 (da) 2014-08-26 2015-08-26 Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering

Country Status (14)

Country Link
US (4) US10406179B2 (da)
EP (4) EP3656869B2 (da)
CA (2) CA3229961A1 (da)
CY (1) CY1123730T1 (da)
DK (2) DK3186395T4 (da)
ES (3) ES2763248T5 (da)
FI (2) FI3656869T4 (da)
HR (1) HRP20210057T4 (da)
HU (2) HUE052725T2 (da)
LT (1) LT3656869T (da)
PL (2) PL3656869T5 (da)
PT (2) PT3186395T (da)
SI (1) SI3656869T2 (da)
WO (1) WO2016033201A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2804617T1 (sl) * 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
FI3656869T4 (fi) 2014-08-26 2025-06-04 Univ Leland Stanford Junior Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
US10550187B2 (en) * 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
HK1249534A1 (zh) 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
EP3341015B2 (en) 2015-08-26 2023-12-27 The Board of Trustees of the Leland Stanford Junior University Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
MX395639B (es) 2017-01-20 2025-03-25 Heidelberg Pharma Res Gmbh Composiciones y métodos para el agotamiento de células cd137+.
JP7321934B2 (ja) * 2017-01-30 2023-08-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 幹細胞移植のための非遺伝毒性移植前処置レジメン
US11078272B2 (en) 2017-03-09 2021-08-03 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of CD47 pathway
JP7262440B2 (ja) 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
US20210198359A1 (en) * 2017-10-25 2021-07-01 Actinium Pharmaceuticals, Inc. Anti-cd45-based lymphodepletion methods and uses thereof in conjction with act-based cancer therapies
WO2019113437A1 (en) * 2017-12-08 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
WO2019234694A2 (en) * 2018-06-07 2019-12-12 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN119684457A (zh) 2018-11-26 2025-03-25 四十七有限责任公司 针对c-kit的人源化抗体
US20220023348A1 (en) 2018-11-28 2022-01-27 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
US20220211885A1 (en) * 2019-04-25 2022-07-07 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
EP3976658A4 (en) * 2019-05-24 2023-06-07 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
WO2022099083A1 (en) * 2020-11-06 2022-05-12 Bluebird Bio, Inc. Methods
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
EP4486784A1 (en) * 2022-03-01 2025-01-08 CSL Innovation Pty Ltd Methods of bone marrow conditioning
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023183555A1 (en) * 2022-03-25 2023-09-28 Memorial Sloan-Kettering Cancer Center Method of promoting thymic recovery by administering hematopoietic stem cells with low c-kit expression
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
EP0932686A2 (en) 1996-10-01 1999-08-04 Geron Corporation Telomerase reverse transcriptase
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
WO2004002425A2 (en) 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
DE60333487D1 (de) * 2002-12-13 2010-09-02 Genetix Pharmaceuticals Inc Therapeutische retrovirus-vektoren für gentherapie
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
ES2882360T3 (es) 2006-11-03 2021-12-01 Univ Leland Stanford Junior Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
EP2477648B1 (en) * 2009-09-15 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
SI2804617T1 (sl) * 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
AU2015229448B2 (en) 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
FI3656869T4 (fi) 2014-08-26 2025-06-04 Univ Leland Stanford Junior Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
US10618976B2 (en) 2015-06-16 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University SIRP-α agonist antibody

Also Published As

Publication number Publication date
HRP20210057T4 (hr) 2025-07-18
EP4257145A3 (en) 2023-10-18
LT3656869T (lt) 2021-01-25
ES2945588T3 (es) 2023-07-04
ES2763248T5 (es) 2023-06-22
CA3229961A1 (en) 2016-03-03
DK3186395T4 (da) 2023-05-08
US20200129557A1 (en) 2020-04-30
US11419897B2 (en) 2022-08-23
PL3186395T3 (pl) 2020-02-28
EP3186395A1 (en) 2017-07-05
CA2958884C (en) 2024-02-27
PL3656869T3 (pl) 2021-05-17
DK3656869T3 (da) 2021-01-04
DK3656869T4 (da) 2025-05-19
SI3656869T2 (sl) 2025-06-30
US20250249042A1 (en) 2025-08-07
HUE052725T2 (hu) 2021-05-28
EP3822364A1 (en) 2021-05-19
US20220347224A1 (en) 2022-11-03
US20170224737A1 (en) 2017-08-10
FI3656869T4 (fi) 2025-06-04
EP3656869A1 (en) 2020-05-27
EP3186395B2 (en) 2023-03-29
EP3656869B1 (en) 2020-11-11
CY1123730T1 (el) 2022-05-27
PL3186395T5 (pl) 2023-06-12
US10406179B2 (en) 2019-09-10
SI3656869T1 (sl) 2021-03-31
EP3822364B1 (en) 2023-05-10
ES2845898T3 (es) 2021-07-28
US12233093B2 (en) 2025-02-25
PT3656869T (pt) 2021-01-13
HRP20210057T1 (hr) 2021-03-05
ES2845898T5 (en) 2025-06-17
CA2958884A1 (en) 2016-03-03
EP3186395B1 (en) 2019-09-25
FI3186395T4 (fi) 2023-05-25
HUE046387T2 (hu) 2020-03-30
PT3186395T (pt) 2019-11-20
EP3186395A4 (en) 2018-03-21
WO2016033201A1 (en) 2016-03-03
ES2763248T3 (es) 2020-05-27
PL3656869T5 (pl) 2025-06-09
EP3656869B2 (en) 2025-04-09
EP3656869A8 (en) 2020-06-10
EP4257145B1 (en) 2025-06-25
EP4257145A2 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
DK3186395T3 (da) Transplantation af stamceller med en kombination af et middel der målretter stamceller og modulation af immunoregulatorisk signalering
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3154561T3 (da) Modulering af komplementaktivitet
DK3240785T3 (da) Småmolekylede hæmmere af laktasedehydrogenase og fremgangsmåder til brug deraf
DK3237597T3 (da) Indretninger til højgennemløbsaggregering og manipulation af pattedyrsceller
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3179992T3 (da) Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
DK3122359T3 (da) Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer
DK3178258T3 (da) Justering af målingsmellemrum og opdagelsessignaler
DK3365684T3 (da) Fremgangsmåde til berigelse af cellefrie nukleosomer
DK3160966T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3071698T3 (da) Excision og indsættelse af stort gen
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
DK3137596T3 (da) Sammensætninger og fremgangsmåder til modulation af komplement faktor b-ekspression
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3048295T3 (da) Fremgangsmåde til opførelse af en vindmølle og vindmølle
DK3508062T3 (da) Herbicid ukrudtsbekæmpelse med kombinationer af fluroxypyr og als-hæmmere
DK3129149T3 (da) Fremgangsmåde til demontering og montering af en ringbandage
DK3198083T3 (da) Undervandsstøjdæmper og fremgangsmåde til håndtering af en undervandsstøjdæmper
DK3389692T3 (da) Modulatorer af komplement-aktivitet
DK3120401T3 (da) System og fremgangsmåder til forebyggelse af kromkontamination af fastoxid-brændselsceller
DK3347342T3 (da) Fremgangsmåde til fremstilling af biguanidin-salte og s-triaziner
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3234058T3 (da) Pakker af metalbeholdere